Nurix Therapeutics Inc. – Filings and Transcripts

NASDAQ: NRIX
Share price (7/6/26): $24.04
Market cap (7/6/26): $2.486 billion

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 02/28/26 Q1

ended 11/30/25 FY 2025

ended 08/31/25 Q3

ended 05/31/25 Q2

ended 02/28/25 Q1

Prospectuses and Registrations Filter

Prospectus supplement for primary offering

Registration of securities for employees

Prospectus supplement for primary offering

Free writing prospectus

Registration of securities for employees

Ownership Filter

News Filter

To Report Updated Phase 1a/B Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy

Announces Global Collaboration With Roche to Co-Develop and Co-Commercialize Potential Best-In-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

Shareholder Vote Results, Financial Statements or Exhibits

Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Other Events, Financial Statements or Exhibits

Proxies Filter

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Other Filter

Scanned paper annual report submission

Scanned paper annual report submission

Letter from the SEC

Correspondence with the SEC

Letter from the SEC